AU2013209344B2 — Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
Assigned to Novartis AG · Expires 2015-12-24 · 10y expired
What this patent protects
H:\fmt\Interwoven\NRPortbl\DCC\FMT\53484I8_I.DOC-25/07/2013 The use of an SiP receptor modulator of the formula (Ia) or (Tb) wherein the meaning of the different residues is that indicated in claim 1, in the preparation of a medicament for preventing, inhibiting or treating an in…
USPTO Abstract
H:\fmt\Interwoven\NRPortbl\DCC\FMT\53484I8_I.DOC-25/07/2013 The use of an SiP receptor modulator of the formula (Ia) or (Tb) wherein the meaning of the different residues is that indicated in claim 1, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis.
Drugs covered by this patent
- Mayzent (SIPONIMOD) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.